

Freedom of Information Request: Our Reference CTMUHB_241_23

You asked:

How many patients have been treated with the following drugs in the past 4 months:

- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepti) - any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) - any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Our response:

Please see below a table populated with the data that Medicines Management are able to provide. The period relates to the last 4 months available which is 1st February 2023 to 31st May 2023.

*Unfortunately, we are unable to provide data relating to Botulinum Toxin because our electronic dispensing system does not record the condition being treated.

This information would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

Medicine	Number of Patients
Erenumab (Aimovig) - any disease	10
Eptinezumab (Vyepti) - any disease	0
Fremanezumab (Ajovy) - any disease	41
Galcanezumab (Emgality) - any disease	6
Rimegepant (Vydura) - any disease	0
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY	*Unable to provide data